Tvardi Therapeutics, Inc. TVRD
1.27
0.21
19.81%
as of 25 Sep
- Market cap
- $14.7M
- P/E
- 0.0×
Follow TVRD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.30 | 2.79 | 2.22 | 1.73 | |
Current Ratio |
3.48 | 2.86 | 2.25 | 1.87 | |
Net Debt/EBITDA |
6.17 | 3.97 | 3.56 | 2.39 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.78 | 0.86 | 1.43 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.02 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.45) | (0.77) | (0.62) | (0.98) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.45) | (0.77) | (0.62) | (0.98) | |
Cash per Share |
3.89 | 4.15 | 2.66 | 1.68 | |
Shareholders Equity per Share |
2.97 | 2.82 | 1.55 | 0.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.97 | 2.82 | 1.55 | 0.89 | |
Free Cash Flow |
(4.26) | (5.68) | (5.86) | (9.23) | |
Working Capital |
27.40 | 20.50 | 14.07 | 7.96 | |
Net Current Asset Value |
27.29 | 20.41 | 14.01 | 7.93 | |
EV/EBIT |
— | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
8.10 | 5.60 | 3.40 | 3.53 | |
Average Assets |
45.18 | 33.64 | 32.38 | 30.63 | |
Average Common Equity |
14.29 | (35.09) | 3.22 | 20.65 |
Columns are period end dates